findmyKOL
Clinical trialNCT03739554CompletedPhase 1Interventional

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

SponsorCyclacel Pharmaceuticals, Inc.Enrollment5Relapsed or Refractory Chronic Lymphocytic Leukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Investigational Site

    Baltimore, Maryland, United States

  • Investigational Site

    Charlotte, North Carolina, United States

  • Investigational Site

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FadraciclibVenetoclax →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
25 Jan 2019
Primary completion
15 Nov 2022
Completion
27 Apr 2023
Last update posted
25 Jan 2024
Registered enrollment
5
Registry id
NCT03739554
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.